Movement Disorders  >>  memantine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
memantine / Generic mfg.
MEMPDD, NCT00630500: Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)

Completed
2
75
Europe
Memantine, Placebo
Helse Stavanger HF, King's College London, Lund University
Dementia Associated With Parkinson's Disease, Dementia With Lewy Bodies
02/09
03/09
2005-004109-27: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies

Ongoing
2
20
Europe
Ebixa, Ebixa, Ebixa
Neuropsychiatric clinic
Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.
 
 

Download Options